Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Recently the United States federal government cancelled $400 million dollars in grants to Columbia University, with $250 ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant ...

Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

Two-year data from a phase 3 trial of exenatide in Parkinson’s is due later this year and could help answer that question, said Prof Foltynie.

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Nausea is a common occurrence for people with diabetes. In some cases, it could be a sign of a life threatening condition that requires swift medical attention. Nausea can take many forms ...

Explore Vivani Medical stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for VANI. EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight ...